Podcasts about Niagara

Even a tiny goldfish can help a mama's heart cope with a big transition.This week's episode is all about Peter the fish — and the surprising emotional waves he created in the Greene household. As Max prepares to leave for college, this unexpected pet helps the family face change, build connection, and rediscover the power of responsibility and love (even if it swims in circles). Rebecca, Seth, and Ella share a heartfelt, humorous, and insightful look into the latest family adventure — and it all starts with a carnival goldfish. From tank mishaps to parenting epiphanies, this episode is full of relatable moments that every parent navigating change will understand. ➡️ Peter the Fish became the newest member of the Greene household after Lily's boyfriend won him at a carnival. What started as a simple bowl turned into a full-on aquatic setup, complete with lessons in goldfish care and responsibility.➡️ Ella shares her poetic moment of sitting at Max's desk, taking care of his cat and fish — calling it a “changing of the guard.” She reflects on what it feels like to step into her brother's world as he begins a new chapter.➡️ Rebecca opens up about how Peter helped her emotionally. Max's room, once a sad place in his absence, now feels warm and comforting thanks to their new pet. Peter has become a small but meaningful way for Rebecca to cope with the transition of her son leaving for college.➡️ The family talks candidly about the reality of pet ownership. Rebecca admits she had no idea how complicated fish care was — but Max took the reins, researched everything, and handled it like a pro.➡️ Parenting reflection: Rebecca wishes she'd introduced pets earlier. Seeing Max take responsibility for Peter showed her how good it is for kids to have something to care for — something that isn't just about themselves.➡️ Life behind the scenes: Lily's Bat Mitzvah planning is in full swing, and Rebecca is deep in it. From décor to logistics, it's become a full-time job, and she shares what this journey has been like emotionally and mentally.➡️ Rebecca and Seth also chat about planning their 20th wedding anniversary celebration — tossing around ideas from Niagara-on-the-Lake to Atlantis in the Bahamas, with lots of laughs along the way.➡️ Don't forget to visit whinypaluza.com and sign up for Rebecca's free parenting resources and weekly emails full of love, tools, and support.➡️ Help Rebecca reach more parents by subscribing, rating, and leaving a short review — it makes a big difference and helps spread Whinypaluza to more amazing families like yours. ➡️ Join the Whinypaluza Moms Facebook Group — it's free, fun, and full of supportive moms who get it. Dont forget to subscribe to this podcast and consider leaving a review! Learn more about your ad choices. Visit megaphone.fm/adchoices

Justin Rogers, Executive Director of the Niagara County fair joins us this morning to discuss the fair on it's opening day. Over a dozen bands, over 50 food vendors, a beer tent, kangaroos, and a massive 14' frying pan all come together to make the Niagara County Fair an event worth experiencing.

In this unplanned guest-less episode, Scott and Dan lean into candid conversation, venting frustrations, sharing personal stories, and reflecting deeply on trauma, empathy, and modern life. They kick things off with a raw discussion about the recurring issue of last-minute guest cancellations and how it feels like disrespect—especially when even a casual, unpaid podcast takes behind-the-scenes effort and planning. The episode then pivots into heavier territory as the brothers address a tragic child murder case, triggering reflections on the ripple effects of trauma in first responder communities. Scott, drawing on his background in homicide, offers heartfelt praise for EMS and correctional officers—groups often overlooked despite their exposure to immense stress and suffering. From there, the tone lightens as Dan recounts a hilariously humbling road rage encounter at Costco and they reflect on everyday moments that shape emotional growth. Their observations on screen addiction in kids lead to admiration for a mom panning for gold with her sons—an impromptu example of parenting done right. They round out the conversation with personal updates: weddings, vacations, time in Niagara-on-the-Lake and Saskatchewan, gym gains, powwow experiences, and some memorable moments from the golf course—including coyotes, ducklings, and a viral video involving a former NHL player and a lake-side altercation.

Comedian and hostess with the mostest Marc withesea joins me for some hilarious insight and chats about comedy. And the Niagara community !

This episode is with Niagara's Rob Repovs, we talk about his work with promoting shows and playing all kinds of venues… even furniture stores? Yes … also about all the events he done and up and coming! Niagara community

Top stories from issues of the past week's Niagara Gazette

Articles and features from the Island Dispatch and the Niagara Tribune

Dateline: July 25, 2025. Rossifari Zoo News is back with a round up of the latest news in the world of zoos, aquariums, conservation, and animal weirdness!   We start off celebrating the fifth anniversary of the podcast! Then it's time for a quick little catch up on me. We then move on to our births for the week, featuring red pandas at Zoo Lodz and Idaho Falls Zoo, and other animals from the Bronx Zoo, Chester Zoo, the Kansas City Zoo and Aquarium, Smithsonian's National Zoo and Conservation Biology Institute, and Cleveland Metroparks Zoo. We then say goodbye to animals from the Aquarium of Niagara and North Carolina Zoo.We have additional Zoo News stories from the ZAA, Oklahoma Aquarium, and the SeaWorld Foundation.Conservation News stories includes robo-bunnies and a look at how crimefighting techniques are being applied to conservation efforts. And in Other News, we talk sloth farts!ROSSIFARI LINKS: patreon.com/rossifari to support the pod rossifari.com @rossifari on socials @rossifaripod on TikTok 

What's up Brian?! This episode is a full-on RGB road trip as we catch up with Bobby Galeza and Mr. Nash after their whirlwind run through Utah, Niagara, and New York Minis — and oh man, it's one for the books. We cover:

Meteorologist Liz Jurkowski has the forecast.

In this episode of Wine Behind the Scenes, Laurel Simmons sat down with Yvonne Irvine, a long-time winemaker in Niagara and the co-founder of Maenad Wine Co. Yvonne shares her journey from studying biotechnology and business to launching a brand that's all about creative freedom, fun, and celebrating women unapologetically. Her wines are low-intervention, playful, and packed with personality from co-ferments with botanicals to pét-nats and piquette blends. They talk about what it means to make wine without the pressure of tradition, why it matters to create space for women in the wine world, and how Yvonne balances a small-scale business with a full-time role and motherhood. What You'll Learn: How Yvonne transitioned from biotech to full-time winemaking The philosophy behind Maenad Wine Co. and what makes it different The role of creativity, nature, and intuition in Yvonne's winemaking process What Yvonne has learned from 18+ years in the Niagara wine industry The realities of sourcing grapes and producing wine on a small scale Why Yvonne believes wine should be approachable, fun, and free of pretense Yvonne Irvine is the co-owner and winemaker of Maenad Wine Co. With over 18 years of experience, she launched Maenad in 2020 to explore experimental, low-intervention winemaking on her terms. Her brand is a tribute to bold, authentic women and to wines that are as expressive as they are accessible. Ready to try something bold in your glass? This episode will inspire you to explore wine differently. Listen now at winebehindthescenes.com

BB Brunes - Coups et blessures Dominique A - Le Twenty-Two Bar Camille Yembe - Coups De Soleil Louane - Maman Archimède - Ça Fly Away Kyo - Hors Du Temps Indochine - 3e sexe Superbus & Rori - Butterfly Cali - C'est quand le bonheur ? Marie-Flore - Promis Jure Big Soul - Le Brio Elisa Tovati & Tom Dice - Il nous faut Calogero - En apesanteur -M- - Machistador Corson - Raise Me Up (Je Respire Encore) St Graal - Je t'emmènerai Deportivo - Parmi Eux Niagara - J'ai Vu Mani - Bang Bang Zaz - Sains Et Saufs Jean-Jacques Goldman - Envole-moi Gregoire - Toi + Moi Jean-Louis Aubert - Tout Y Est Clara Luciani - Courage Tibz - On n'est pas bien là ? Rori - Vérité Axelle Red - Je T'attends Céphaz - On a Mangé le soleil Pierre Garnier - Ce Qui Me Va Matmatah - Lambe An Dro Noé Preszow - A Nous Vivien Savage - La p'tite Lady Minuit - Flash Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Meteorologist Phillip Pandolfo has today's forecast, as well as an outlook for the rest of the week.

This week Chris, Jason, Jamie and Lew get into their early criminal activity, Lew's vices, genetics vs environment, Escobar and a columbian idiot and sudoku causes prolapses.  

In the first episode of "Double Identity," we kick off our new film noir podcast series. We thought it'd be fun to bring a high school film teacher and a former Private investigator perspectives together to explore the world of film noir. After some good debate and a few deep cuts, we decide on five films to cover: Laura, The Big Sleep, The Big Heat, Niagara, and the Bob Hope parody My Favorite Brunette. Follow along with us and watch Laura before the next episode.

Aaron Berger and C.D Onofrio form a Sea of Gold and Burgundy join me in the studio! They have new music and we chat about their journey in Mexico and how the Niagara community has grown. So happy to have them on. The vizzy show

Niagara Comedian Tommy J Warren joins me not the show, join us as we chat about then Niagara comedy scene and being a dad and a stand up comedian . The Community is amazing for comedy and its growing

Buffalo-native Steve Tybor is back home with Eight Days of Hope, assisting residents of the city's Niagara District with home repairs. He tells us about the work they're doing.

Top stories from issues of the past week's Niagara Gazette

Articles and features from the Island Dispatch and the Niagara Tribune

Vernis Rouge & Zaoui - Comme des loups Matmatah - Lambe An Dro Kyo - Je Cours Santa - La différence Vivien Savage - La p'tite Lady Hoshi - Nouveau Jour Gaëtan Roussel - Inoubliable Marylyn - Un Peu De Mal Lisa Pariente - Pas banale Vanessa Paradis - Bouquet Final Saez - Jeune et con Boulevard Des Airs - Bruxelles Fredericks, Goldman, Jones - A nos actes manqués Daniel Balavoine - Aimer est plus fort que d'être aimé Charlotte Cardin - Confetti Sinclair - Ensemble Corson - Raise Me Up (Je Respire Encore) Renaud - Dès que le vent soufflera Styleto - Amour Cyclone Dan Black & Louane - Orchestra Zazie - Zen Jean-Louis Aubert - Tout Y Est Helena - Mauvais Garçon Serge Gainsbourg - No Comment Marguerite - Les Filles, Les Meufs Etienne Daho - Mon Manege A Moi Elisa Tovati & Tom Dice - Il nous faut Calogero - Passage des cyclones Aaron - Le Tunnel D'or BB Brunes - Coups et blessures Niagara - Je dois m'en aller Raphael - Et Dans 150 Ans Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Country music legend Grandpa Jones' signature song — “Eight More Miles to Louisville” — started out celebrating a journey that was nearly twice as long and to an entirely different city.About a decade before Grandpa recorded his tune, Alton and Rabon Delmore of Alabama's famed Delmore Brothers were playing their “Fifteen Miles from Birmingham” on live radio shows as the duo trekked across the South.That song was never a big hit for the Delmores — by then, they had many hits, including “Got the Kansas City Blues” (1931), “Brown's Ferry Blues” (1934), “I'm Alabama Bound” (1939), “Freight Train Boogie” (1946) — but the Birmingham tune strongly inspired Jones. He rewrote it into a song with similar themes of nostalgia, longing for home and the comfort of familiar surroundings, but with new lyrics that shifted the focus north to Louisville.By the way, both Jones and the Delmores might have borrowed the tune from a third source. In 1927 the same melody was played on the fiddle and sung to entirely different lyrics by Virginia's Shelor Family on their song "Big Bend Gal." It's possible the Delmores and Jones both were influenced by that recording.Kentucky Born and BredWhen Jones recorded his new tune in the spring of 1946, he was paying tribute his beloved home state. Born Louis Marshall Jones in 1913, he grew up in the tiny farming community of Niagara, Ky., in Henderson County, 130 miles west of Louisville.His was a musical family — his father played old-time fiddle and his mother sang ballads —and young Louis's first instrument was the guitar.Jones spent his teenage years in Akron, Ohio, singing on country music shows on WJW Radio. In 1931, he joined the Pine Ridge String Band, which provided the musical accompaniment for the popular syndicated “Lum and Abner” comedy program in the NBC radio network.“Grandpa” is BornTo grow his music career, Jones next moved to Boston in 1935 to work at WBZ Radio. It was in that studio's band that he had a fateful meeting with singer/songwriter Bradley Kincaid. Famously, Kincaid used to tease the 22-year-old fellow Kentuckian for always being grumpy when he came to the studio to do the early morning broadcast, so Kincaid nicknamed him “Grandpa Jones.”Louis liked the name and decided to create an entire stage persona based on it. The “grandpa” character served him for the remaining 60 years of his life, from his regular appearances on the Grand Ole Opry starting in 1946 to TV's “Hee Haw” in the 1970s and ‘80s. Jones used to tell interviewers the only difference was that over the years he needed less and less makeup to achieve his signature look.Enter the BanjoPerforming as Grandpa Jones, he played guitar, yodeled and sang mostly old-timey ballads. Then in 1937, Jones made another fateful trip, this time to Wheeling, WV, where he worked on WWVA Radio with Cousin Emmy (Cynthia May Carver).It was she who taught Jones the clawhammer style of banjo playing, which gave him a rough backwoods flavor to his performances. That was Jones' distinctive sound from then on.In 1944, at age 31, Jones put his career on hold when he enlisted in the army during World War II. Discharged two years later, he was ready to resume recording with King Records. All he needed was a theme song. That bill was filled by “Eight More Miles to Louisville,” which he released on May 28, 1946. After that, Grandpa Jones performed it at virtually every one of his shows for the next half century.Our Take on the TuneSometimes the only thing that will fit bill is a song from your youth. All of us grew up hearing Grandpa's famous theme song.Here's a take from this week's rehearsal, with Randy Hamilton singing the lead and everybody joining in on the choruses. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit 1937flood.substack.com

Sugar cane in coke,Ostrich farm update,Fentanyl is schedule 1 Uk to lower voting age to 16 in the next general election,Hockey canada and gender ideology,X's pron bots,Niagara falls isn't a Canadian city anymore,Checklist for going live:Name of stream changedIntro songGood Morning, Everyone! Today is date#Cpd #lpc, #ppc, #ndp, #canadianpolitics, #humor, #funny, #republican, #maga, #mcga,Sign Up for the Full ShowLocals (daily video)Sample Showshttps://canadapoli2.locals.com/ Spotify https://podcasters.spotify.com/pod/show/canadapoli/subscribePrivate Full podcast audio https://canadapoli.com/feed/canadapoliblue/Buy subscriptions here (daily video and audio podcast):https://canadapoli.cm/canadapoli-subscriptions/Youtubehttps://www.youtube.com/c/CanadaPoli/videosMe on Telegramhttps://t.me/realCanadaPoliMe on Rumblehttps://rumble.com/user/CanadaPoli Me on Odysseyhttps://odysee.com/@CanadaPoli:f Me on Bitchutehttps://www.bitchute.com/channel/l55JBxrgT3Hf/ Podcast RSShttps://anchor.fm/s/e57706d8/podcast/rsso

More oppressive heat is on the way Wednesday. Meteorologist Aaron Reynolds has the forecast.

The story so far: After being trapped under ground for over a year in a mysterious movie store called "Moleman's Movie Hole," the boys still find ways to entertain themselves...typically with movies.This week, Eric's back! And after mistakingly grabbing the wrong movie off the shelf, we sit back to watch the 1986 horror/thriller classic The Hitcher! Come for the discussion on the greatness of Rutger Hauer, stay for the tangents about Eric's hitchhiking stories, where bodies would realistically get torn apart, and Dan's cool wife and their Niagara vacation! Hop in, we're taking a ride together! Leave us a 30 second voicemail and if we like it we'll play it on the show: (949) 4-STABBY (949-478-2229)Next movie announced every Wednesday. New episodes every Monday. Follow us on the things: Linktree: https://www.linktr.ee/stabbystabbyInstagram:  @stabbypod  https://www.instagram.com/stabbypod/Letterboxd:   https://boxd.it/dp1ACMerch: https://www.big-other.com/shop/stabby-stabbySend us a text

On this weeks bonus episode of OFF AIR we discuss classic game shows, funny athlete names, how many gatherings do we need and Lew has a mouse.

Articles and features from the Island Dispatch and the Niagara Tribune

Top stories from issues of the past week's Niagara Gazette

The grace of God is always flowing, always constant, always cascading – just like the Bible describes it. -------- Thank you for listening! Your support of Joni and Friends helps make this show possible.     Joni and Friends envisions a world where every person with a disability finds hope, dignity, and their place in the body of Christ. Become part of the global movement today at www.joniandfriends.org   Find more encouragement on Instagram, TikTok, Facebook, and YouTube.

Colton Lackey, Development Director at Niagara Gospel Mission tells us how the nonprofit was able to recover so quickly.

Niagara Frontier Automobile Dealers Association President Paul Stasiak weighs in on Big Beautiful Bill's potential impact on car buying bonus 322 Tue, 08 Jul 2025 09:00:00 +0000 Hy0ypyMf2m4wTqw47FckclcF2Aa4GKud news WBEN Extras news Niagara Frontier Automobile Dealers Association President Paul Stasiak weighs in on Big Beautiful Bill's potential impact on car buying Archive of various reports and news events 2024 © 2021 Audacy, Inc. News

On this week's OFF AIR, the worst hockey nickname, was Helen Keller a scam, which celebs would be good hangs and the best of medieval torture. ENJOY!

Articles and features from the Island Dispatch and the Niagara Tribune

Top stories from issues of the past week's Niagara Gazette

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain, both practicing community oncologists, are joined by Dr. Tian Zhang from UT Southwestern to discuss key highlights from the ASCO 2025 annual meeting, focusing on genitourinary (GU) malignancies. Episode Highlights: • KEYNOTE-564: discussed 5 years OS data, reinforcing the role of adjuvant pembrolizumab in renal cell carcinoma • AMPLITUDE: combination of PARP inhibitor niraparib with abiraterone improved progression-free survival in patients with homologous recombination repair mutations in metastatic hormone-sensitive prostate cancer • ARANOTE: positive quality of life impact when using darolutamide in metastatic hormone-sensitive prostate cancer, which is also FDA approved now • NIAGARA: the prognostic value of ctDNA in muscle-invasive bladder cancer, emphasizing its implications for treatment strategies YouTube: https://youtu.be/Rt8HQpdyVY0 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Join us as we break down these important studies and their potential to change clinical practice in oncology. Don't forget to check out our other episodes for more insights into cancer care!

Colton Lackey with Niagara Gospel Mission on a need for food donations after freezer accidents over the weekend full 233 Wed, 02 Jul 2025 07:58:00 +0000 A9tUIYH6Ap0TJWlXT7QkNEGjKfz2vPJK news & politics,news WBEN Extras news & politics,news Colton Lackey with Niagara Gospel Mission on a need for food donations after freezer accidents over the weekend Archive of various reports and news events 2024 © 2021 Audacy, Inc. News & Politics News False

WBEN's Tom Puckett on a food crisis for Niagara Gospel Mission full 59 Wed, 02 Jul 2025 07:55:00 +0000 FULJdzduAMDKUm6tU8HRxrhGFe7j2rzv news & politics,news WBEN Extras news & politics,news WBEN's Tom Puckett on a food crisis for Niagara Gospel Mission Archive of various reports and news events 2024 © 2021 Audacy, Inc. News & Politics News False https://player.amperwavepodcas

Happy Canada Jay Day.  It's July 1, 2025 and for most people it's a holiday and a chance to  barbecue, picnic, get away from the house and watch or set off fireworks after dark.  For birders,(those poor souls that have to work for a living during the week), it's a day to celebrate birds and go birding with friends, family, or just get away on your own and and listen to the summer breeding birds in a quiet forest, park or glen.  As I write this, I'm sitting on a quiet bench in Long Point, Ontario at the Long Point Bird Banding Demonstration Station at what they call the Old Cut.          Since last we visited, a lot has gone on in the birding world here in Southwestern Ontario.  I still have yet to see a Wilson's Warbler, but hopefully fall migration will bring one my way.  Aside from that, the last month has been good to me.  I saw a Laughing Gull in Toronto and Sue and I found, and listened to an Acadian Flycatcher in the oddly named Skunk's Misery.  The other amazing happening, has been an eruption of American White Pelicans that have refused to fly north and west to their breeding grounds.  They've been spotted all over southwestern Ontario.  The big news for the local birders, was that 9 of those pelicans are visiting us where I live in Brantford.  They first appeared on the Grand River at Waterworks Park, only minutes from home. And happily, this batch of, perhaps bachelor pelicans, has stuck around and may, verily, spend the summer with us on The Grand.      I only added 11 birds to my year list in June, many of those I should have seen during migration.  But not that sinker, the Willson's Warbler.  Look, I can understand missing a Worm Eating Warbler,(and yes,I confess I missed that one too), but for Audubon's sake, really, one of the easiest spring warblers, the bright yellow bird with the black yarmulka, described by American ornithologist Alexander Wilson in 1811!  And it's a bird that seems to have little fear of peoples as it hunts bugs and such in the outsides of branches, like dogwoods, in the spring.  So yeah, am I bitter?  Heck yeah!       Okay, take a deep breath. Center yourself.  Breath. It's just one bird.  Not like I missed a Brown Pelican.  Oh yeah, a Brown Pelican showed up in the Niagara region this past Monday. I raced to Niagara-on-the Lake, searched the buoy it had been on, but the heat haze made it impossible to be sure I was looking at it, maybe it was there, maybe it wasn't. By the time I was able to see the  buoy clearly in the afternoon, it was long gone.  But missed opportunities lead to future celebrations when you finally do see the bird you've been searching for all year.  Your patience,(and mine),may one day be rewarded.      Now on to the show.  My guests are a birding couple from Maine, Ingrid and Ethan Whitaker.  Ethan set the record,(since broken), for a Maine Big Year on his own and then Ingrid got into the Big Year spirit so they could see the country, maybe see 600 species of birds, and, for some reason, a giant ball of twine.  They weren't chasing any records, but were more successful than they ever imagined when they set out on their Lower 48 Big Year.  Please enjoy as Ethan and Ingrid Whitaker tell the rest of the story.      Next month, we'll be venturing back in time to the year 2012 and returning to Ontario.  At the beginning of that year I was a 51 yr old, less than novice birder and had started an ABA Big Year on a wing and a prayer.  My guest, however, not even half my age at the time, was an experienced and knowledgeable birder and was setting out on his Ontario Big Year.  It ended up being a battle worth of Kenn Kauffman and Floyd Murdoch back in 1973.  Suffice it to say, my guest, Andrew Keaveny, played the part of Kenn Kauffman.  During the course of 2012 I got to know Andrew very well, and often I was able to follow up on his finds and get birds I may not have seen otherwise.  We have become good birding friends over the years and it will be nice to finally hear his story.      Once again, I wish I could thank everyone personally for listening.  You could do me a big favour by following, subscribing, liking and commenting, wherever it is you listen to my voice over the ethereal land of podcasts.  Also, please tell all your birding friends and family to come have a listen.  Won't you?  

On this weeks episode of OFF AIR, we get into classic school pranks, we saved a mayor's career, Chris' sweat don't stink and Lew is turned on by the national anthem.

Articles and features from the Island Dispatch and the Niagara Tribune

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News.  I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode.  Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC.   Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings.  So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease.  So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting.  So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting.  So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response.  So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma.  So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025.  So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence.  So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj.  Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer.  So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response.  These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months.  Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup.  So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj.  Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial.  A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion.  So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance.  So, thank you, Jeanny, for joining me today and sharing your insights.  And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Neeraj Agarwal     @neerajaiims     Dr. Jeanny Aragon-Ching   Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,    Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

The Outer Realm welcomes the return of dear Friend and special guest, Niagara Historian Dave Bennison Host: Michelle Desrochers Date: June 24th, 2025 Episode: 580 Discussion : Part 2 - Dave is well versed and well researched. He will be sharing a lot of historical information about the Niagara Region, just in time for tourist season! War of 1812, Butlers Rangers, The Forts throughout the Niagara Falls Region, The St Lawrence Seaway/Welland Canal, The Near Full Mastadon Skeleton found in Wainfleet, Ontario and now lies at the Royal Ontario Museum in Toronto, Laura Secord and much more!!! Contact for the show - theouterrealmcontact@gmail.com Rumble: TheOuterRealm X - MicheleDerocher Website: www.theouterrealmradio.com Please support us by Liking, Subscribing, Sharing and Commenting. Thank you all !!! About Dave : Dave is Is a 28 year veteran Truck driver who a few years ago started a side project as a Radio host interviewing Celebrities. Artists Musicians Historians And Paranormal experts His love of History sparked the creation of an Online Webseries called Historical Niagara that has become very popular .Each week exploring The History of Southern Ontario and Western New York. Dave lives in Welland Ont and Also carves Staffs ,Canes and pendants made from Historic wood. His Wife Victoria even wrote a book about it Called Stick to the Story . Social Media FB https://www.facebook.com/HistoricalNiagara?mibextid=LQQJ4d If you enjoy the content on the channel, please support us by subscribing: Thank you All A formal disclosure: The opinions and information presented or expressed by guests on The Outer Realm Radio and Beyond The Outer Realm are not necessarily those of the TOR, BTOR Hosts, Sponsors, or the United Public Radio Network and its producers. Although the content may be interesting, it is deemed "For Entertainment Purposes" . We are always be respectful and courteous to all involved. Thank you, we appreciate you all!

What makes old Malbec vines planted in the 1920s so rare and valuable today? Why would a Canadian winemaker head to Mendoza, Argentina, to start a winery? What's one of the biggest challenges holding back Canadian wine and how can consumers change that? In this episode of the Unreserved Wine Talk podcast, I'm chatting with Ann Sperling & Peter Gamble. You can find the wines we discussed at https://www.nataliemaclean.com/winepicks   Highlights What makes Devotion different from other On Seven wines? What inspired Peter to look beyond Canada to Argentina for winemaking? How did he decide on the particular vineyard to purchase? What is massal selection in viticulture? How did Versado end up with such old vines, and how does this show up in the wine? Are there aspects of Malbec that are similar to Pinot? How have Ann and Peter revitalized the Leily Winery? What are the differences and similarities between Leily and On Seven Chardonnays? What would Ann and Peter like their legacies to be in the Canadian wine industry? What are the greatest threats to the Canadian wine industry? Which three figures in the wine industry would Peter invite to a dream dinner party?   Key Takeaways In the 1905 to 1925 period in Argentina, winemakers at the time planted the greatest genetic diversity amongst the Malbec vines, because they were still learning about it. Their Versado vineyard reflects that time when genetic diversity was appreciated. We visited a lot of wine regions in the world for the meetings, both fun and a necessity, and one of them was Mendoza and loved the climate - a really interesting climate from the point of view of creating flavors and grapes, and really liked the lifestyle as well. We essentially decided it'd be interesting to do something small there that also gives us a second harvest during New Year's. So we can practice twice as often. That was the driver, the potential quality there. They've been talking about this for probably the 40 years that they've been making wine and and they want to figure out how to have lasting consumer engagement. They have a lot of devoted buyers, but they also know kind of the monopoly culture is that, well, if the wine you were looking for today isn't on the shelf, you can buy something else. Promoting the message of buying directly from the wineries, and if you want to try that wine that's made in Nova Scotia or BC, that you actually can order it and have it shipped to your home province. Those interprovincial trade barriers aren't real. There's lots of wine shipping that's taking place already. Just get on your computer like you do with so many other products that you buy and buy online.   About Ann Sperling & Peter Gamble Often referred to as the “power couple” of the Canadian wine industry, Peter Gamble and Ann Sperling have long pursued the pinnacles of wine quality in Canadian vineyards and wineries. Following her upbringing on her family's Okanagan Valley vineyard, Ann turned to the soil for the character and complexity of her wines. Acknowledged as a Canadian pioneer of organic and biodynamic viticulture, ‘terroir' was at the centre of her philosophy and she is renowned for her head winemaking roles at Malivoire, Southbrook, and Sperling Vineyards. Peter, a lifetime wine industry professional, has worked alongside Canada's most passionate winemakers to achieve greater heights with our finest appellation wines. Since 2000, Peter has provided expertise in ultra-premium winemaking operations, including: Stratus, Ravine, Benjamin Bridge and Lightfoot & Wolfville. With the purchase of a top-flight ancient Malbec planting in Mendoza, Argentina, in 2008, Ann and Peter broadened their winemaking activities, but Niagara remains their cherished home base. Current focus is on these Niagara projects: On Seven, Lailey and Stonebridge Vineyards and Dobbin Estate.         To learn more, visit https://www.nataliemaclean.com/343.

It occurred to me that I've never posted a recording from Mansion House as a Soul Shack mix, so I figured with me playing there this Saturday for The Grape & Wine Festival (old, but I am there this Friday for Canada Day weekend), why not post my mix from when I was there in August. Most of the time I get to play inside (instead of the patio) which gives me the freedom musically to play like this mix (as opposed to the patio, where I would need to play more mainstream party bangers for the college crowd). So check it out, hope you enjoy, and if you're in Niagara, come see me this Friday June 27th for Canada Day! (and if you're anywhere in Niagara, Hamilton or The GTA and need a dj for a wedding, birthday or summer party, give me a call!)Subscribe on Apple Podcasts: https://podcasts.apple.com/podcast/id306968245Follow on Instagram: https://www.instagram.com/dj_j_meBookings & Merch: jamiewichartz @ yahoo.ca

This week on your bonus OFF AIR episode Lew is back. We get into Golf, Religion and good ole moustache rubbin'. 

Top stories from issues of the past week's Niagara Gazette

You know how when you have a good idea, you get a little lightbulb over your head? What if you had a bad idea, and a million cubic feet of rock collapsed on you.On today's episode: why the tourist bureau for today's story drink so much; how the people in today's episode work with equipment that would rattle an melt your skull off and sometimes want to cry and eat each other; and why the phrase “well, I'm glad that's all over” is rarely misapplied this badly.And because you are listening to this as a Patreon supporter, you get to enjoy an additional 10 minutes where we discuss: the hodge podge of brutalized bones and missing appendages that have sailed over the Falls; you'd hear about the increasingly ill-conceived and sketchy reasons people have tried their luck over the Falls on purpose; you would hear the tales of two waterways widely described as “inhospitable to human survival; and you would learn about the only unintentional subaquatic river trolley in the world.Niagara Falls has always been a magnet for honeymooners, daredevils, stunt performers and industrialists, but there is no place more ready to delete you from your travel itinerary in so many permanent and awful ways. It's also been a magnet for nature-inspired calamity. This is our second episode from this exotic location, and I could do an entire episode on just the daredevils alone. I really wanted to record this episode at Niagara Falls, but I also wanted to get it out in the first half of 2025, so no dice. That said, you can't do an episode about Niagara Falls without talking about the numbers of people who “take that vertical swim” on purpose.If you or someone you know sounds like they'd like to visit the Falls so-to-speak, please don't hesitate to reach out. There are people ready to help.In Canada, Talk Suicide Canada at 1-833-456-4566 (Available 24/7) or text 45645, or visit www.crisisservicescanada.ca. For youth and young adults, there is also Kids Help Phone at 1-800-668-6868 or text CONNECT to 686868.In the United States, you can call the 988 Suicide & Crisis Lifeline: just dial 988 (Available 24/7) or you can text HOME to 741741In the UK, you can reach the Samaratins at 116 123.Obviously, this kind of thing that can be hard to talk about, but this is a show filled with things that can be hard to listen to. You're already brave. Use that bravery to pick up a phone and please take care of yourself. All older episodes can be found on any of your favorite channelsApple : https://tinyurl.com/5fnbumdw Spotify : https://tinyurl.com/73tb3uuw IHeartRadio : https://tinyurl.com/vwczpv5j Podchaser : https://tinyurl.com/263kda6w Stitcher : https://tinyurl.com/mcyxt6vw Google : https://tinyurl.com/3fjfxatt Spreaker : https://tinyurl.com/fm5y22su Podchaser : https://tinyurl.com/263kda6w RadioPublic : https://tinyurl.com/w67b4kec PocketCasts. : https://pca.st/ef1165v3 CastBox : https://tinyurl.com/4xjpptdr Breaker. : https://tinyurl.com/4cbpfayt Deezer. : https://tinyurl.com/5nmexvwt Follow us on the socials for moreFacebook : www.facebook.com/doomsdaypodcast Instagram : www.instagram.com/doomsdaypodcast Twitter : www.twitter.com/doomsdaypodcast TikTok : https://www.tiktok.com/@doomsday.the.podcast If you like the idea of your podcast hosts wearing more than duct tape and bits of old Halloween costumes for clothes and can spare a buck or two, you can now buy me a coffee at www.buymeacoffee.com/doomsday or join the patreon at www.funeralkazoo.com/doomsday

Dateline: June 20, 2025. Rossifari Zoo News is back with a round up of the latest news in the world of zoos, aquariums, conservation, and animal weirdness!   We start off with a quick catch up on me. We then move on to our births for the week, featuring animals from Aquarium of Niagara, Southwick's Zoo, Zoo Miami, Sequoia Park Zoo, Franklin Park Zoo, Minnesota Zoo, Binder Park Zoo, and more.We then say goodbye to animals from Buttonwood Park Zoo, Denver Zoo, Hogle Zoo, Adelaide Zoo, and Chattanooga Zoo.We have additional Zoo News stories from the Columbus Zoo, Smithsonian's National Zoo, Perth Zoo, Fort Worth Zoo, Trevor-Lovejoy Zoo, and more! Conservation News stories includes updating pangolin protections, a rediscovery, and more! And in Other News, it's Ed the zebra.ROSSIFARI LINKS: patreon.com/rossifari to support the pod rossifari.com @rossifari on socials @rossifaripod on TikTok 

On this weeks bonus episode of OFF MIC we talk about jerks who send food back, we find out about Lew's body hair regiment and Jason wants to murder fans. Good times.

Liberty Dispatch Interviews ~June 07, 2025In this episode of Liberty Dispatch Interviews, host Andrew DeBartolo speaks with Harold Jonker, a former Niagara region councillor and a key figure in the Freedom Convoy. They discuss Harold's experiences during and after the convoy, including the legal challenges he faced, the role of the integrity commissioner, and the importance of Christian involvement in politics. In celebration of Harold's legal vindication, enjoy this full interview for free! For full access to all our content, become a paid subscriber at: Liberty Dispatch Substack ldcanada.substack.com Canadian news, culture, and political analysis from a Christian perspective. Episode Resources: Freedom Convoy victory: Trucker Harold Jonker cleared of all charges in Ontario court: https://www.jccf.ca/freedom-convoy-victory-trucker-harold-jonker-cleared-of-all-charges-in-ontario-court/; SHOW SPONSORS: Go to https://PIAVPN.com/LibertyDispatchto get 83% off from our sponsor, Private Internet Access, with 4 months free! Invest with Rocklinc: info@rocklinc.com or call them at 905-631-546; Diversify Your Money with Bull Bitcoin: https://mission.bullbitcoin.com/dispatch; BarterPay: https://barterpay.ca/; Barter It: https://www.barterit.ca/; Get freedom from Censorious CRMS by signing up for SalesNexus: https://www.salesnexus.com/ SUBSCRIBE TO OUR SHOWS/CHANNELS: LIBERTY DISPATCH PODCAST: https://libertydispatch.podbean.com; https://rumble.com/LDshow; CONTACT US: libertydispatch@pm.me STAY UP-TO-DATE ON ALL THINGS LD:Instagram: https://www.instagram.com/liberty_dispatch/; Facebook: https://www.facebook.com/LibertyDispatchCanada; X: @LDCanada - https://x.com/_LDCanada; Rumble: https://rumble.com/LDshow; YouTube: https://www.youtube.com/@libertydispatch Please LIKE, SUBSCRIBE, RATE, & REVIEW, and SHARE it with others!